bs-21429R **[Primary Antibody]**

CYP7A1 Rabbit pAb

www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

DATASHEET

Host: Rabbit **Isotype:** IgG

Clonality: Polyclonal

GeneID: 1581 **SWISS:** P22680

Target: CYP7A1

Immunogen: KLH conjugated synthetic peptide derived from human CYP7A1: 321-421/504.

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This endoplasmic reticulum membrane protein catalyzes the first reaction in the cholesterol catabolic pathway in the liver, which converts cholesterol to bile acids. This reaction is the rate limiting step and the major site of regulation of bile acid synthesis, which is the primary mechanism for the removal of cholesterol from the body. Polymorphisms in the promoter of this gene are associated with defects in bile acid synthesis. [provided by RefSeq, Feb 2010].

Applications: **WB** (1:500-2000)

Reactivity: Mouse (predicted: Human, Rat)

Predicted MW.: 55 kDa

Subcellular Location: Cell membrane

VALIDATION IMAGES



Sample: Liver (Mouse) Lysate at 40 ug Primary: Anti-CYP7A1 (bs-21429R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 55 kD Observed band size: 55 kD

SELECTED CITATIONS

- **[IF=7.9]** Li Xiao. et al. Kaempferol ameliorated alcoholic liver disease through inhibiting hepatic bile acid synthesis by targeting intestinal FXR-FGF15 signaling. PHYTOMEDICINE. 2023 Nov;120:155055 WB ;Mouse. 37678053
- **[IF=6.9]** Dongmei Qin. et al. Lupeol improves bile acid metabolism and metabolic dysfunction-associated steatotic liver disease in mice via FXR signaling pathway and gut-liver axis. BIOMED PHARMACOTHER. 2024 Aug;177:116942 WB ;Mouse. 38889641
- **[IF=6.684]** Wu P. et al. Arbutin Alleviates the Liver Injury of α-Naphthylisothiocyanate-induced Cholestasis Through Farnesoid X Receptor Activation.. Front Cell Dev Biol. 2021 Dec;9:758632-758632 WB ;Mouse. 34926449
- **[IF=6.656]** Dina Tawulie. et al. Jiang-Tang-San-Huang pill alleviates type 2 diabetes mellitus through modulating the gut microbiota and bile acids metabolism. PHYTOMEDICINE. 2023 Feb;:154733 WB ;Rat. 36870307

- **[IF=4.546]** Li S et al. Dietary Betaine Addition Promotes Hepatic Cholesterol Synthesis, Bile Acid Conversion, and Export in Rats. Nutrients. 2020 May 13;12(5):1399. WB ;Rat. 32414094